Mitochondrial Pyruvate Carriers are Required for Myocardial Stress Adaptation

[1]  O. Ilkayeva,et al.  Nutritional modulation of heart failure in mitochondrial pyruvate carrier–deficient mice , 2020, Nature Metabolism.

[2]  M. Crespo-Leiro,et al.  Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy , 2020, Nature Metabolism.

[3]  David S. Wishart,et al.  Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis , 2019, Current protocols in bioinformatics.

[4]  A. Galaz,et al.  Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments , 2019, The Journal of Biological Chemistry.

[5]  R. Shields,et al.  Impaired skeletal muscle mitochondrial pyruvate uptake rewires glucose metabolism to drive whole-body leanness , 2019, eLife.

[6]  Rick B. Vega,et al.  The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. , 2019, JCI insight.

[7]  A. Sherry,et al.  Effects of deuteration on transamination and oxidation of hyperpolarized 13C-Pyruvate in the isolated heart. , 2019, Journal of magnetic resonance.

[8]  K. Gopal,et al.  Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. , 2019, Cardiovascular research.

[9]  B. Lauzier,et al.  Protein O-GlcNAcylation in Cardiac Pathologies: Past, Present, Future , 2019, Front. Endocrinol..

[10]  Hai-Bin Ruan,et al.  Ketone bodies as epigenetic modifiers , 2018, Current opinion in clinical nutrition and metabolic care.

[11]  G. Lopaschuk,et al.  Loss of Metabolic Flexibility in the Failing Heart , 2018, Front. Cardiovasc. Med..

[12]  G. Brooks.  The Science and Translation of Lactate Shuttle Theory. , 2018, Cell metabolism.

[13]  E. Lewandowski,et al.  Enhanced Redox State and Efficiency of Glucose Oxidation With miR Based Suppression of Maladaptive NADPH-Dependent Malic Enzyme 1 Expression in Hypertrophied Hearts , 2018, Circulation research.

[14]  Charlotte R. Feddersen,et al.  The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity , 2017, Molecular metabolism.

[15]  E. Taylor.  Functional Properties of the Mitochondrial Carrier System. , 2017, Trends in cell biology.

[16]  M. Young,et al.  Metabolic Origins of Heart Failure , 2017, JACC. Basic to translational science.

[17]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[18]  J. Tardif,et al.  Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia. , 2016, American journal of physiology. Heart and circulatory physiology.

[19]  Stephen L. Johnson,et al.  Lactate Metabolism is Associated with Mammalian Mitochondria , 2016, Nature chemical biology.

[20]  Benoît Vanderperre,et al.  Embryonic Lethality of Mitochondrial Pyruvate Carrier 1 Deficient Mouse Can Be Rescued by a Ketogenic Diet , 2016, PLoS genetics.

[21]  Rick B. Vega,et al.  The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.

[22]  N. Domenech,et al.  Analysis of Mitochondrial Proteins in the Surviving Myocardium after Ischemia Identifies Mitochondrial Pyruvate Carrier Expression as Possible Mediator of Tissue Viability* , 2015, Molecular & Cellular Proteomics.

[23]  J. Rutter,et al.  Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis and Whole-Body Glucose Homeostasis. , 2015, Cell metabolism.

[24]  J. Colca,et al.  Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling. , 2015, Cell metabolism.

[25]  Gary J. Patti,et al.  X13CMS: Global Tracking of Isotopic Labels in Untargeted Metabolomics , 2014, Analytical chemistry.

[26]  Torsten Doenst,et al.  Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production , 2013, Circulation research.

[27]  J. Wikswo,et al.  Amino acids as metabolic substrates during cardiac ischemia , 2012, Experimental biology and medicine.

[28]  E. Lewandowski,et al.  In vivo, cardiac-specific knockdown of a target protein, malic enzyme-1, in rat via adenoviral delivery of DNA for non-native miRNA. , 2012, Current gene therapy.

[29]  A. Halestrap.  The mitochondrial pyruvate carrier: has it been unearthed at last? , 2012, Cell metabolism.

[30]  Claire Redin,et al.  A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans , 2012, Science.

[31]  J. Veuthey,et al.  Identification and Functional Expression of the Mitochondrial Pyruvate Carrier , 2012, Science.

[32]  Jian Ye,et al.  Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction , 2012, BMC Bioinformatics.

[33]  Torsten Doenst,et al.  PGC-1&bgr; Deficiency Accelerates the Transition to Heart Failure in Pressure Overload Hypertrophy , 2011, Circulation research.

[34]  Yibin Wang,et al.  Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? , 2011, Cardiovascular research.

[35]  S. Lloyd,et al.  Cardiac anaplerosis in health and disease: food for thought. , 2011, Cardiovascular research.

[36]  Heinrich Taegtmeyer,et al.  Substrate–Enzyme Competition Attenuates Upregulated Anaplerotic Flux Through Malic Enzyme in Hypertrophied Rat Heart and Restores Triacylglyceride Content: Attenuating Upregulated Anaplerosis in Hypertrophy , 2009, Circulation research.

[37]  G. Mercuro,et al.  The role of amino acids in the modulation of cardiac metabolism during ischemia and heart failure. , 2008, Current pharmaceutical design.

[38]  B. Stieger.  Faculty Opinions recommendation of Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies. , 2007 .

[39]  U. Andersson,et al.  Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies. , 2007, Archives of biochemistry and biophysics.

[40]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[41]  B. Lorell,et al.  Mechanisms for Increased Glycolysis in the Hypertrophied Rat Heart , 2004, Hypertension.

[42]  H. Leong,et al.  Glycolysis and pyruvate oxidation in cardiac hypertrophy--why so unbalanced? , 2003, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[43]  S. Kalhan,et al.  The Key Role of Anaplerosis and Cataplerosis for Citric Acid Cycle Function* , 2002, Journal of Biological Chemistry.

[44]  M. Gibala,et al.  Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle. , 2000, Acta physiologica Scandinavica.

[45]  B. Lowell,et al.  Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. , 1999, The Journal of clinical investigation.

[46]  C. Rosiers,et al.  Probing the Origin of Acetyl-CoA and Oxaloacetate Entering the Citric Acid Cycle from the 13C Labeling of Citrate Released by Perfused Rat Hearts* , 1997, The Journal of Biological Chemistry.

[47]  C. Rosiers,et al.  A 13C Mass Isotopomer Study of Anaplerotic Pyruvate Carboxylation in Perfused Rat Hearts* , 1997, The Journal of Biological Chemistry.

[48]  J. Lommi,et al.  Blood ketone bodies in congestive heart failure. , 1996, Journal of the American College of Cardiology.

[49]  G. Lopaschuk,et al.  Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. , 1994, The American journal of physiology.

[50]  Y. Kanno,et al.  Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study. , 1990, Circulation.

[51]  O. Pisarenko,et al.  The role of amino acid catabolism in the formation of the tricarboxylic acid cycle intermediates and ammonia in anoxic rat heart. , 1986, Biochimica et biophysica acta.

[52]  J. Hiltunen,et al.  Role of pyruvate carboxylation in the energy-linked regulation of pool sizes of tricarboxylic acid-cycle intermediates in the myocardium. , 1982, The Biochemical journal.

[53]  A. Sols,et al.  Pyruvate dehydrogenase complex of ascites tumour. Activation by AMP and other properties of potential significance in metabolic regulation. , 1980, The Biochemical journal.

[54]  R. Denton,et al.  The specificity and metabolic implications of the inhibition of pyruvate transport in isolated mitochondria and intact tissue preparations by alpha-Cyano-4-hydroxycinnamate and related compounds. , 1975, The Biochemical journal.

[55]  L. Opie,et al.  The Value of Lactate and Pyruvate Measurements in the Assessment of the Redox State of Free Nicotinamide‐Adenine Dinucleotide in the Cytoplasm of Perfused Rat Heart , 1971, European journal of clinical investigation.

[56]  H. Krebs,et al.  The redox state of the nicotinamide-adenine dinucleotides in rat liver homogenates. , 1968, The Biochemical journal.

[57]  D. Stapleton,et al.  Proceedings of the Australian Physiological Society Symposium Myocardial glycogen dynamics: New perspectives on disease mechanisms , 2015 .

[58]  C. Des Rosiers,et al.  Metabolic Tracing Using Stable Isotope-Labeled Substrates and Mass Spectrometry in the Perfused Mouse Heart. , 2015, Methods in enzymology.

[59]  D. Blacker.  Food for thought. , 2013, JAMA neurology.

[60]  G. Lopaschuk,et al.  An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. , 1993, The Journal of pharmacology and experimental therapeutics.